The FDA has accepted Organogenesis’ Biologics License Application (BLA) for ReNu, an investigational treatment for knee osteoarthritis. The regulatory milestone marks a key step toward the potential approval of a non-surgical therapy for patients with persistent knee pain.
Written by: Anshu Gupta (PharmD)
Reviewed By: Pharmacally Editorial Team
Organogenesis has cleared an important regulatory milestone after the U.S. Food and Drug Administration accepted its Biologics License Application for ReNu®, a cryopreserved amniotic suspension allograft developed to treat pain associated with symptomatic knee osteoarthritis (OA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 24, 2027.
If approved, ReNu, for which the FDA has conditionally accepted the proprietary name Amnuvx (azimplacel), could become the first biologic therapy approved for non-surgical treatment of knee OA pain. The product is intended for patients whose symptoms persist despite conservative management but who are not yet candidates for joint replacement surgery.
Regenerative Allograft Targets a Major Unmet Need
Knee osteoarthritis is a progressive degenerative joint disease affecting nearly 31 million Americans, with prevalence projected to exceed 34 million by 2027. The condition is a leading cause of chronic pain, disability, and reduced quality of life, often resulting in diminished mobility and functional impairment.
While existing therapies primarily provide symptomatic relief, patients with advanced disease frequently progress to total knee replacement once non-surgical options no longer provide adequate benefit.
ReNu is a cryopreserved amniotic suspension allograft composed of amniotic fluid cells and micronized amniotic membrane. The therapy contains naturally occurring cellular components, growth factors, and extracellular matrix proteins that are intended to support tissue repair and modulate inflammation associated with osteoarthritis.
Clinical Development Supported by Three Randomized Trials
The BLA is supported by data from three randomized controlled trials involving more than 1,300 patients with symptomatic knee osteoarthritis, including two pivotal Phase 3 studies. The first Phase 3 trial (NCT04636229) met its primary endpoint, while the second (NCT06000410) demonstrated numerical improvement in pain reduction and significant functional benefit, contributing to the overall evidence package submitted to the FDA.
The therapy previously received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation in 2021, recognizing its potential to address an unmet medical need in patients with knee osteoarthritis and providing opportunities for enhanced regulatory interactions during development.
Company Highlights Regulatory Progress
Patrick Bilbo, Chief Operating Officer of Organogenesis, said the FDA’s acceptance of the BLA represents an important step toward expanding treatment options for patients living with knee osteoarthritis. He noted that the company will continue working closely with the agency throughout the review process as it advances ReNu toward potential commercialization.
Regulatory Path Forward
With the BLA now under FDA review, Organogenesis will work with regulators through the standard evaluation process ahead of the April 24, 2027 PDUFA deadline. Approval would establish ReNu, marketed under the proposed proprietary name Amnuvx, as a novel biologic treatment option for symptomatic knee osteoarthritis and could expand the therapeutic landscape between conservative care and total knee replacement surgery.
What This Means to Patient
If approved, ReNu (proposed proprietary name: Amnuvx) could become the first FDA-approved biologic therapy for pain associated with symptomatic knee osteoarthritis. As a regenerative amniotic suspension allograft containing cells, growth factors, and extracellular matrix components, the therapy represents a novel biological approach that differs from conventional pain-relieving injections. While it is not intended to reverse osteoarthritis or replace joint replacement surgery, it may offer patients a new treatment option that could reduce pain, improve physical function, and potentially delay the need for surgery in appropriately selected individuals. The FDA’s decision, expected by April 24, 2027, will determine whether this new therapeutic approach becomes available in clinical practice.
Refrences
About the Writer
Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.